Hello friends and fellow traders. We hope you all had a great weekend, especially considering the lackluster start to the new trading week. We're not terribly surprised, actually. This pre-Christmas-break week is usually a fairly dead one, and slightly bearish more often than not. The Santa Claus rally -- if we get one -- only applies to the few days between the holiday day-off and New Year's Day. And yet, once again despite the lethargic beginning, we've got plenty to talk about. Before it even has a chance to get buried within everything else we've got for you today, note that we'll be sending a new trading idea to you tomorrow morning, right around the open. It's a cannabis play, which continues to be one of the market's few bright spots right now. And, as we've suggested more than once of late, this stock isn't a direct play on recreational or medicinal marijuana or cannabinoids, but rather, an indirect "support" play... where the real money in the business is being made. Remember, it wasn't the gold miners and prospectors that made all the money in the gold rush of 1849. It was the people selling pickaxes and shovels that did remarkably well. This company is more of a facilitator of a better breed of cannabis product, and its patents mean nobody else can do what it's doing. The really cool part about Tuesday's idea? It's not just some theory. The business is already up and running. It's just that a recent cannabis deal is likely to turn up the heat on the stock. It'll all make perfect sense come tomorrow morning. Stay tuned. In the meantime, one of our already-featured stocks made a little news today. Lexaria Pharmaceuticals (LXRP) -- which has engineered a way of enhancing a human body's absorption of vitamins, minerals, and other compounds -- has filed for an international patent for a couple of its technologies. As Bryan Murphy hashes out, this is a subtle sign of the company's overseas ambitions. Lexaria is another one of those cannabis names that isn't selling or growing marijuana, but rather, building a business that helps consumers and other companies get more out of an existing, proven hemp/marijuana business. LXRP has done well of late, and we expect no less from tomorrow's stock. In the meantime, let's talk about the market, shall we? As easy as it would be to blame today's slight intraday pullback from an already-weak advance on what happened in Berlin (it appears to be some sort of terror-like act as of the time we're putting the newsletter together today), we don't think that's the key culprit. Our feeling is the market is simply struggling to tack on more gains following the post-election runup of 8%. Investors want a little more convincing stocks are worth the risk of higher prices from here, and they haven't quite gotten in yet. Today's volume was tepid from the get-go. The good news is, the S&P 500's semi-important line in the sand at 2250 hasn't been breached yet. The VIX is inching lower too. The bad news is, the VIX doesn't have any meaningful amount of room to keep moving lower, which works against the market. With that as the backdrop, once again I thought John Monroe over at the Elite Opportunity Pro newsletter had the most reasonable and actionable assessment of what's going on with the market right now. He explained of the S&P 500 index in today's edition of the EO Pro: "At this point, we've got a small triangle wedge developing, as evidenced by the daily chart of the S&P 500 below. As you can see here, the highs have gotten lower over the last few days, but the lows have yet to be breached. We suspect that wedge will be busted in either direction as soon as today or tomorrow, and based on the fact the S&P 500 continues to hover right around our previously published target of 2,288, we're assuming the breach will be to the downside when it's all said and done. Just how low the markets will want to go before they find their footing again remains the question. I mentioned the possibility of roughly 2,160 on the S&P 500 last week, but I also mentioned the possibility of a few days below the 3X3 DMA (blue line) you see in this daily chart here before the index could snap back in sharp fashion. If the latter happens, and more importantly the markets quickly find their footing on the heels of that move, we could see the markets rally into the end of the year. Typically, when the markets have a great November, like the one we've had this year, they tend to follow through about 80% of the time, so if these markets are really going to stage an extremely sharp selloff, I suspect it's not going to happen until some point early next year when investors take profits, rather than posting those capital gains in 2016." I hadn't really seen the S&P 500's short-term wedge until he pointed it out, but he's exactly right. And, it's going to play a role in how things shake out for the market from here. The question is, how? Next week and the very beginning of January are supposed to be a bullish time of year. We suspect the same is in the cards as 2016 turns into 2017, which as John suggested, postpones any pullback until we take a couple of steps into the new year. It seems unlikely the bulls are going to let the bears do any real damage over the course of the next two weeks (not that the bears were interested in doing so), even though we're due for a corrective move. In any case, while we're touching on it briefly here, I strongly recommend you heed John's advice by subscribing to the Elite Opportunity Pro newsletter today. He's get a firm grip on where things are headed, and he's turning that insight into winning trades on a regular basis. We only scratched the surface here. As an example, one of his most recent index-based trades -- a trade on the Direxion Daily Small Cap Bull 3X ETF (TNA) -- ended up reaping a 44% gain when Elite Opportunity Pro subscribers closed it out last month. If your portfolio could use a few extra double-digit winners every year, become an EO Pro member today. And don't forget to check your inbox tomorrow morning right around the open. This new trading idea is a real show-stopper.